

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

06 Jun 2026

### The effect of minocycline on the symptoms of schizophrenia, a randomized double blind controlled clinical trial

#### Protocol summary

ghanizad@sina.tums.ac.ir

##### Summary

This is a double-blind, randomized, placebo-controlled clinical trial investigating the efficacy of minocycline for the treatment of schizophrenia. Sixty patients with schizophrenia diagnosed using DSM-IV are randomly allocated in a 2:1 ratio to minocycline (200 mg/d) or placebo group. The patients will receive usual medication (typical and atypical antipsychotics). Therefore, minocycline is added to the medications. Alcohol dependency, pregnancy, and breast feeding are among the exclusive criteria. The duration of this study is 8 weeks. Clinical assessment will be occurred at baseline (Pre-intervention), week 2, week 4 and week 8.

##### Recruitment status

**Recruitment complete**

##### Funding source

Shiraz University of Medical Sciences

##### Expected recruitment start date

2011-09-23, 1390/07/01

##### Expected recruitment end date

2012-09-22, 1391/07/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201108223930N12**

Registration date: **2011-11-08, 1390/08/17**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2011-11-08, 1390/08/17

##### Registrant information

###### Name

Ahmad Ghanizadeh

###### Name of organization / entity

Research Center for Psychiatry and Behavioral Sciences, Shiraz University Of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 71 1627 3070

###### Email address

##### Scientific title

The effect of minocycline on the symptoms of schizophrenia, a randomized double blind controlled clinical trial

##### Public title

The effect of minocycline on the symptoms of schizophrenia

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion Criteria: Age of 18-65 years; both genders; diagnosed Schizophrenia using DSM-IV diagnostic criteria; capable and willing to provide written informed consent by the patients and/or caregiver. Exclusion Criteria: Alcohol dependency; known or suspected pregnancy; women who are breastfeeding; and a known contraindication to minocycline treatment.

##### Age

From **18 years** old to **65 years** old

##### Gender

Both

##### Phase

2

## Groups that have been masked

No information

## Sample size

Target sample size: 60

## Randomization (investigator's opinion)

Randomized

## Randomization description

## Blinding (investigator's opinion)

Double blinded

## Blinding description

## Placebo

Used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Shiraz University of Medical Sciences

##### Street address

Vice-chancellery of Research Affairs, Shiraz University of Medical sciences, Zand Street

##### City

Shiraz

##### Postal code

#### Approval date

2011-08-28, 1390/06/06

#### Ethics committee reference number

CT-90-5661

## Health conditions studied

### 1

#### Description of health condition studied

schizophrenia

#### ICD-10 code

F20

#### ICD-10 code description

Schizophrenia

## Primary outcomes

### 1

#### Description

Positive and Negative Syndrome Scale for schizophrenia

#### Timepoint

(Pre-intervention), 2nd week, 4th week and 8th week

#### Method of measurement

Interview

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

minocycline 200 mg/day

#### Category

Treatment - Drugs

### 2

#### Description

Placebo

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Research Center for Psychiatry and Behavioral Sciences

##### Full name of responsible person

Motahhar Omrani

##### Street address

Hafez hospital, Chamran Street

##### City

Shiraz

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Shiraz University of Medical Sciences

##### Full name of responsible person

Gholamreza Hatam

##### Street address

Vice-chancellery of Research Affairs, Shiraz University of Medical sciences, Zand Street

##### City

Shiraz

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Shiraz University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

empty

#### Domestic or foreign origin

empty

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

*empty*

**Phone**

+98 71 1627 3070

**Fax****Email**

ghanizad@sina.tums.ac.ir

**Web page address****Person responsible for general inquiries****Contact****Person responsible for scientific inquiries****Contact****Name of organization / entity**

Shiraz University of Medical sciences

**Full name of responsible person**

Ahmad Ghanizadeh

**Position**

MD

**Other areas of specialty/work****Street address**

Hafez Hospital, Chamran street

**City**

Shiraz

**Postal code****Person responsible for updating data****Contact****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*